- Oral presentation
- Open Access
Antibodies induced by immunization with a hypoallergenic mutant of the major fish allergen Cyp c 1 inhibit allergic symptoms in a mouse model of fish allergy
© Gstoettner et al; licensee BioMed Central Ltd. 2013
Published: 25 July 2013
Fish allergy is one of the most frequently occurring allergies to animal-derived food and may cause severe anaphylactic reactions. Currently allergen-specific immunotherapy for fish allergy is not available as it may induce severe side-effects. A hypoallergenic mutant of the major carp allergen Cyp c 1 (mCyp c 1) has recently been developed for the treatment of IgE-mediated fish allergy. We analysed the effect of antibodies induced by immunization with mCyp c 1 on allergic symptoms in a mouse model of fish allergy.
C3H/HeJ mice were sensitized to Cyp c 1 by intragastric gavage or subcutaneous immunization using Cholera toxin or aluminium hydroxide as adjuvans, respectively. Rabbits were immunized with the recombinant mCyp c 1. Antibody responses to mCyp c 1 and wild-type Cyp c 1 were investigated by ELISA using 7 overlapping Cyp c 1-derived synthetic peptides. In order to study if mCyp c 1-specific antibodies can protect, Cyp c 1-sensitized mice received mCyp c 1-specific or control antibodies before they were challenged orally with Cyp c 1.
Intragastric sensitization of C3H/HeJ mice induced Cyp c 1-specific IgE antibodies, which did not bind to Cyp c 1-derived peptides, indicating sensitization to conformational epitopes. Rabbit anti-mCyp c 1-specific IgG antibodies recognized the wildtype Cyp c 1 allergen and also reacted with peptide epitopes. They were able to block human and mouse IgE-binding to rCyp c 1 in vitro. In vivo administration of mCyp c 1-specific IgG antibodies reduced allergic symptoms after oral allergen challenge demonstrating that allergen-specific IgG antibodies can protect against food allergy.
Vaccination with mCyp c 1 induces IgG antibody responses, which can protect against fish allergy in a murine model.
This work was supported by the FAST project of the FP7 of the European Union.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.